Low doses of antigen coupled to anti-CR2 mAbs induce rapid and enduring IgG immune responses in mice and in cynomolgus monkeys

Molecular Immunology

Volumn 44, Issue 4, 2007, Pages 377-388

  Whipple, Emily C ^a   Ditto, Andrew H ^a   Shanahan, Ryan S ^a   Gatesman, Jeremy J ^a   Little, Stephen F ^b   Taylor, Ronald P ^a   Lindorfer, Margaret A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Anthrax protective antigen; Antigen presentation; B lymphocytes; Complement; Vaccination

Indexed keywords

7G6 MONOCLONAL ANTIBODY; ANTHRAX PROTECTIVE ANTIGEN; ANTHRAX TOXIN; ANTIBODY; ANTIGEN; COMPLEMENT RECEPTOR 2 MONOCLONAL ANTIBODY; HAPTEN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; B LYMPHOCYTE; BIOTINYLATION; CELL ADHESION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLICULAR DENDRITIC CELL; IMMUNE RESPONSE; IMMUNIZATION; LOW DRUG DOSE; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGEN PRESENTATION; IMMUNIZATION; IMMUNOGLOBULIN G; MACACA FASCICULARIS; MICE; MICE, INBRED BALB C; RATS; RECEPTORS, COMPLEMENT 3D;

ALEXA; MACACA FASCICULARIS; PRIMATES;

EID: 33747868712     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2006.02.032     Document Type: Article

References (58)

1. Aloni-Grinstein R., Gat O., Altboum Z., Velan B., Cohen S., and Shafferman A. Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen. Infect. Immun. 73 (2005) 4043-4053
2. Applequist S.E., Dahlstrom J., Jiang N., Molina H., and Heyman B. Antibody production in mice deficient for complement receptors 1 and 2 can be induced by IgG/Ag and IgE/Ag, but not IgM/Ag complexes. J. Immunol. 165 (2000) 2398-2403
3. Aulinger B.A., Roehrl M.H., Mekalanos J.J., Collier R.J., and Wang J.Y. Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines. Infect. Immunity 73 (2005) 3408-3414
4. Baiu D.C., Preschl J., Tchorbanov A., Molina H.D., Erdei A., Sulica A., Capel P.J.A., and Hazenbos W.L.W. Modulation of the humoral immune response by antibody-mediated antigen targeting to complement receptors and Fc receptors. J. Immunol. 162 (1999) 3125-3130
5. Bayer E.A., and Wilchek M. The use of avidin-biotin complex as a tool in molecular biology. Methods Biochem. Anal. 26 (1980) 1-45
6. Boyaka P.N., Tafaro A., Fischer R., Leppla S.H., Fujihashi K., and McGhee J.R. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol. 170 (2003) 5636-5643
7. Brown J.C., De Jesus D.G., and Holborow E.J. Lymphocyte-mediated transport of aggregated human γ-globulin into germinal centre areas of normal mouse spleen. Nature 228 (1970) 367-369
8. Brown J.C., Harris G., Papamichail M., Sljivic V.S., and Holborow E.J. The localization of aggregated human γ-globulin in the spleens of normal mice. Immunology 24 (1973) 955-968
9. Carroll M.C. The role of complement in B cell activation and tolerance. Adv. Immunol. 74 (2000) 61-88
10. Carroll M.C. The complement system in regulation of adaptive immunity. Nat. Immunol. 5 (2004) 981-985
11. Chabot D.J., Scorpio A., Tobery S.A., Little S.F., Norris S.L., and Friedlander A.M. Anthrax capsule vaccine protects against experimental infection. Vaccine 23 (2004) 43-47
12. Chang J.H., Sutherland W.M., and Parsons S.J. Monoclonal antibodies to oncoproteins. Methods Enzymol. 254 (1995) 430-445
13. Croix D.A., Ahearn J.M., Rosengard A.M., Han S., Kelsoe G., Ma M., and Carroll M.C. Antibody response to a T-dependent antigen requires B cell expression of complement receptors. J. Exp. Med. 183 (1996) 1857-1864
14. Dempsey P.W., Allison M.E., Akkaraju S., Goodnow C.C., and Fearon D.T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271 (1996) 348-350
15. Fang Y., Chenguang X., Yang-Xin F., Holers M., and Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J. Immunol. 160 (1998) 5273-5279
16. Fearon D.T., and Carroll M.C. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu. Rev. Immunol. 18 (2000) 393-422
17. Ferguson A.R., Youd M.E., and Corley R.B. Marginal zone B cells transport and deposit IgM-containing immune complexes onto follicular dendritic cells. Intl. Immunol. 16 (2004) 1411-1422
18. Fischer M.B., Ma M., Goerg S., Zhou X., Xia J., Finco O., Han S., Kelsoe G., Howard R.G., Rothstein T.L., Kremmer E., Rosen S., et al. Regulation of the B cell response to T-dependent antigen by classical pathway complement. J. Immunol. 157 (1996) 549-556
19. Getahun A., Dahlstrom J., Wernersson S., and Heyman B. IgG2a-mediated enhancement of antibody and T cell responses and its relation to inhibitory and activating Fcγ receptors. J. Immunol. 172 (2004) 5269-5276
20. Gor D.O., Ding X., Li Q., and Greenspan N.S. Genetic fusion of three tandem copies of murine C3d sequences to diptheria toxin fragment B elicits a decreased fragment B-specific antibody response. Immunol. Lett. 102 (2005) 38-49
21. Gray D., Kumararatne D.S., Lortan J., Khan M., and MacLennan I.C.M. Relation of intra-splenic migration of marginal zone B cells to antigen localization on follicular dendritic cells. Immunology 52 (1984) 659-669
22. Gray D., McConnell I., Kumararatne D.S., MacLennan I.C.M., Humphrey J.H., and Bazin H. Marginal zone B cells express CR1 and CR2 receptors. Eur. J. Immunol. 14 (1984) 47-52
23. Guthridge J.M., Young K., Gipson M.G., Sarrias M.R., Szakonyi G., Chen X.S., Malaspina A., Donoghue E., James J.A., Lambris J.D., Moir S.A., Perkins S.J., et al. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface. J. Immunol. 167 (2001) 5758-5766
24. Haas K.M., Hasegawa M., Steeber D.A., Poe J.C., Zabel M.D., Bock C.B., Karp D.R., Briles D.E., Weis J.H., and Tedder T.F. Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses. Immunity 17 (2002) 713-723
25. Haas K.M., Toapanta F.R., Oliver J.A., Poe J.C., Weis J.H., Karp D.R., Bower J.F., Ross T.M., and Tedder T.F. C3d functions as a molecular adjuvant in the absence of CD21/35 expression. J. Immunol. 172 (2004) 5833-5837
26. Harms G., Hardonk M.J., and Timens W. In vitro complement-dependent binding and in vivo kinetics of pneumococcal polysaccharide TI-2 antigens in the rat spleen marginal zone and follicle. Infect. Immun. 64 (1996) 4220-4225
27. Henson S.E., Smith D., Boackle S.A., Holers V.M., and Karp D.R. Generation of recombinant human C3dg tetramers for the analysis of CD21 binding and function. J. Immunol. Methods 258 (2001) 97-109
28. Hermanson G., Whitlow V., Parker S., Tonsky K., Rusalov D., Ferrari M., Lalor P., Komai M., Mere R., Bell M., Brenneman K., Mateczun A., et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 13601-13606
29. Heyman B. Regulation of antibody responses via antibodies, complement, and Fc receptors. Ann. Rev. Immunol. 18 (2000) 709-737
30. Heyman B., Wiersma E.J., and Kinoshita T. In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody. J. Exp. Med. 172 (1990) 665-668
31. Humphrey J.H., Grennan D., and Sundaram V. The origin of follicular dendritic cells in the mouse and the mechanism of trapping of immune complexes on them. Eur. J. Immunol. 14 (1984) 859-864
32. Jendrek S., Little S.F., Hem S., Mitra G., and Giardina S. Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants. Vaccine 21 (2003) 3011-3018
33. Kenney R.T., Yu J., Guebre-Xabier M., Frech S.A., Lambert A., Heller B.A., Ellingsworth L.R., Eyles J.E., Williamson E.D., and Glenn G.M. Induction of protective immunity against lethal anthrax challenge with a patch. J. Infect. Dis. 190 (2004) 774-783
34. Kinoshita T., Thyphronitis G., Tsokos G.C., Finkelman F.D., Hong K., Sakai H., and Inoue K. Characterization of murine complement receptor type 2 and its immunological cross-reactivity with type 1 receptor. Int. Immunol. 2 (1990) 651-659
35. Klinman D.M., Xie H., Little S.F., Currie D., and Ivins B.E. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine 22 (2004) 2881-2886
36. Lee Y., Haas K.M., Gor D.O., Ding X., Karp D.R., Greenspan N.S., Poe J.C., and Tedder T.F. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement. J. Immunol. 175 (2005) 8011-8023
37. Lindorfer M.A., Jinivizian H.B., Foley P.L., Kennedy A.D., Solga M.D., and Taylor R.P. The B cell complement receptor 2 transfer reaction. J. Immunol. 170 (2003) 3671-3678
38. Lindorfer M.A., Nardin A., Foley P.L., Solga M.D., Bankovich A.J., Martin E.N., Henderson A.L., Price C.W., Gyimesi E., Wozencraft C.P., Goldberg J.B., Sutherland W.M., et al. Targeting of Pseudomonas aeruginosa in the bloodstream with bispecific monoclonal antibodies. J. Immunol. 167 (2001) 2240-2249
39. Little S.F., Ivines B.E., Fellows P.F., Pitt M.L.M., Norris S.L.W., and Andrews G.P. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22 (2003) 422-430
40. Little S.F., Leppla S.H., and Cora E. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect. Immun. 56 (1988) 1807-1813
41. Llopis M.J., Harms G., Hardonk M., and Timens W. Human immune response to pneumococcal polysaccharides: complement-mediated localization preferentially on CD21-positive splenic marginal zone B cells and follicular dendritic cells. J. Allergy Clin. Immunol. 97 (1996) 1015-1024
42. Matyas G.R., Friedlander A.M., Glenn G.M., Little S., Yu J., and Alving C.R. Needle-free skin patch vaccination method for anthrax. Infect. Immun. 72 (2004) 1181-1183
43. Mikszta J.A., Sullivan V.J., Dean C., Waterston A.M., Alarcon J.B., Dekker III J.P., Brittingham J.M., Huang J., Hwang C.R., Ferriter M., Jiang G., Mar K., et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis. 191 (2005) 278-288
44. Pepys M.B. Role of complement in induction of antibody production in vivo. J. Exp. Med. 140 (1974) 126-145
45. Pozdnyakova O., Guttormsen H.K., Lalani F.N., Carroll M.C., and Kasper D.L. Impaired antibody response to group B streptococcal type III capsular polysaccharide in C3- and complement receptor 2-deficient mice. J. Immunol. 170 (2003) 84-90
46. Prechl J., Tchorbanov A., Horvath A., Baiu D.C., Hazenbos W., Rajnavolgyi E., Kurucz I., Capel P.J.A., and Erdei A. Targeting of influenza epitopes to murine CR1/CR2 using single-chain antibodies. Immunopharmacology 42 (1999) 159-165
47. Prodinger W.M., Schwendinger M.G., Schoch J., Kochle M., Larcher C., and Dierich M.P. Characterization of C3dg binding to a recess formed between short consensus repeats 1 and 2 of complement receptor type 2 (CR2; CD21). J. Immunol. 161 (1998) 4604-4610
48. Rhie G., Roehrl M., Mourez M., Collier R.J., Mekalanos J.J., and Wang J. A dually active anthrax vaccine that confers protection against both bacilli and toxins. PNAS 100 (2003) 10925-10930
49. Riemenschneider J., Garrison A., Geisbert J., Jahrling P., Hevey M., Negley D., Schmaljohn A., Lee J., Hart M.K., Vanderzanden L., Custer D., Bray M., et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 21 (2003) 4071-4080
50. Ross T.M., Xu Y., Bright R.A., and Robinson H.L. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat. Immunol. 1 (2000) 127-131
51. Ross T.M., Xu Y., Green T.D., Montefiori D.C., and Robinson H. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res. Human Retroviruses 17 (2001) 829-835
52. Taylor R.P., Sutherland W.M., Martin E.N., Ferguson P.J., Reinagel M.L., Gilbert E., Lopez K., Incardona N.L., and Ochs H.D. Bispecific monoclonal antibody complexes bound to primate erythrocyte CR1 facilitate virus clearance in a monkey model. J. Immunol. 158 (1997) 842-850
53. Tedder T.F., Clement L.T., and Cooper M.D. Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody. J. Immunol. 133 (1984) 678-683
54. Thyphronitis G., Kinoshita T., Inoue K., Schweinle J.E., Tsokos G.C., Metcalf E.S., Finkelman F.D., and Balow J.E. Modulation of mouse complement receptors 1 and 2 suppresses antibody responses in vivo. J. Immunol. 147 (1991) 224-230
55. van den Berg T.K., Yoshida K., and Dijkstra C.D. Mechanism of immune complex trapping by follicular dendritic cells. Curr. Top. Microbiol. Immunol. 201 (1995) 49-63
56. Wang L., Sunyer O., and Bello L.J. Fusion to C3d enhances immunogenicity of the E2 glycoprotein of type 2 bovine viral diarrhea virus. J. Virol. 78 (2004) 1616-1622
57. Whipple E.C., Shanahan R.S., Ditto A.H., Taylor R.P., and Lindorfer M.A. Analyses of the in vivo trafficking of stoichiometric doses of an anti-complement receptor 1/2 monoclonal antibody infused intravenously in mice. J. Immunol. 173 (2004) 2297-2306
58. Xie H., Gursel I., Ivins B.E., Singh M., O'Hagan D.T., Ulmer J.B., and Klinman D.M. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect. Immun. 73 (2005) 828-833